Russell Charles J, Penkert Rhiannon R, Kim Sonnie, Hurwitz Julia L
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Pathogens. 2020 Feb 13;9(2):109. doi: 10.3390/pathogens9020109.
Human metapneumovirus (HMPV) infects most children by five years of age. The virus can cause both upper and lower respiratory tract disease and can be life threatening. High-risk populations include young children who are exposed to virus for the first time and the elderly. Currently, there is no standard treatment nor licensed vaccine for HMPV, although several attractive vaccine candidates have been developed for pre-clinical studies. A raised awareness of the impact of HMPV on public health is needed to drive research, complete vaccine development, and thereby prevent significant virus-associated morbidities and mortalities worldwide.
人偏肺病毒(HMPV)在大多数儿童5岁前就会感染他们。该病毒可引起上呼吸道和下呼吸道疾病,甚至可能危及生命。高危人群包括首次接触该病毒的幼儿和老年人。目前,针对HMPV尚无标准治疗方法,也没有获得许可的疫苗,不过已经开发出了几种有吸引力的候选疫苗用于临床前研究。需要提高对HMPV对公共卫生影响的认识,以推动研究、完成疫苗开发,从而预防全球范围内与该病毒相关的重大发病和死亡情况。